Detail akcie Landec Corp online

Business Summary: Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
Financial Summary: BRIEF: For the fiscal year ended 28 May 2023, Lifecore Biomedical Inc revenues decreased 7% to $103.3M. Net loss before extraordinary items increased from $15.5M to $64.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Loss on debt refinancing increase from $0K to $23.7M (expense), Transition services income decrease of 94% to $349K (income).